From Facebook rants to podcasts hosts to outlier physicians, there is a vocal minority of Americans who believe that ivermectin is a viable and underutilized therapy for patients with COVID-19. As is most often the case, that does not necessarily reflect the best evidence-based practice. JAMA Internal Medicine just published an article that could be helpful in separating fact from misinformation and disinformation. The study on which the article was based randomized subjects to receive either standard of care plus ivermectin or standard of care alone. In short, there was no evidence that the standard-of-care-plus-ivermectin group derived any benefit compared with the standard-of-care-alone group.
Skip the Chatter and Focus on the Research When It Comes to Ivermectin